INKT Earnings Date & History
Mink Therapeutics Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:19 PM ET
Mink Therapeutics Inc
Biotechnology
- Next earnings date
- Thursday, November 12, 2026
- Reporting session
- Before Open
- EPS estimate
- $-0.64
- Revenue estimate
- $0
INKT earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-0.61 | $-0.62 | -1.3% | $0 |
| Friday, May 15, 2026 | Q1 2026 | $-0.79 | $-0.57 | +27.4% | $0 |
| Tuesday, March 31, 2026 | Q4 2025 | $-0.84 | $-0.56 | +33.6% | $0 |
| Friday, November 14, 2025 | Q3 2025 | $-0.87 | $-0.65 | +25.5% | $0 |
| Thursday, August 14, 2025 | Q2 2025 | $-0.56 | $-1.06 | -90.1% | $0 |
What the market is watching in INKT's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next INKT earnings date?
- Mink Therapeutics Inc is scheduled to report on Thursday, November 12, 2026 (Before Open). Dates can change until the company confirms them.
- Does INKT report before or after the market?
- The next report is scheduled before open.
- What EPS is expected for INKT?
- Consensus EPS for the upcoming quarter is $-0.64, on revenue of $0.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
INKT earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.